News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT starts DIABECELL® Phase IIb trial

Living Cell Technologies Limited
Company Announcement

LCT starts DIABECELL® Phase IIb trial in Argentina

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a Phase IIb trial of DIABECELL®.

The trial is designed to demonstrate the clinical benefits of DIABECELL in unstable type 1 diabetes. Twenty patients will receive two implants of 10,000 IEQ/kg (islet equivalents per kilogram of body weight), with the second implant occurring 12 weeks after the first. This is the dose which was shown to be most clinically effective in reducing HbA1c, insulin dose and unaware hypoglycaemic events in the interim analysis of the Phase I/IIa trial in Argentina, announced today.

The principal investigator of the Phase IIb trial is Dr Adrián Abalovich of Hospital Eva Perón in San Martín, Buenos Aires.

“We are using an ‘adaptive trial design’ for our pivotal studies and so the data generated in this 20 patient trial will likely form the foundation data for our registration package,” said Dr Andrea Grant, Chief Executive, LCT. “We remain on track to meet our goal of completing clinical trials of DIABECELL by 2015 and having a product commercially available by 2016.”

DIABECELL is a breakthrough treatment for people with unstable type 1 diabetes and is the first islet transplant treatment that does not require ongoing administration of debilitating immunosuppression drugs. DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.


– Ends –

For further information: www.lctglobal.com

About DIABECELL
Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and pregnancy complications and shortened life expectancy.
Treatment with DIABECELL® involves transplanting pig pancreatic islet cells into a patient’s abdomen to boost insulin production and help regulate blood glucose levels. The cells are encapsulated with IMMUPEL™ to prevent the immune system rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without the patient requiring immunosuppressant drugs.
DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.
For a summary of DIABECELL’s clinical trial programme please see the DIABECELL clinical trial update on LCT’s website www.lctglobal.com or DIABECELL clinical trial update.

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and in Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson’s disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

The Last Dambuster: Death Of Les Munro

The Governor-General has noted the passing of Les Munro, the last remaining airman from the Dambuster Raid: “In this year where we are marking the 70th anniversary of the end of the Second World War, it is more important than ever to honour the veterans of that conflict..." More>>

ALSO:

Album Review And Rap Beefs: Tame Impala, Currents.

Tame Impala’s new album Currents has one of the hallmarks of an enduring album. At first listen it seems like good, if somewhat ordinary, pop but as you go back more and more layers unravel revealing deeply rich, expertly crafted songs. More>>

Flagging Enthusiasm: Gareth Morgan Announces Winner Of $20k Flag Competition

The winner of the Morgan Foundation’s $20,000 flag competition is “Wā kāinga / Home”, designed by Auckland based Studio Alexander. Economist and philanthropist Gareth Morgan set up the competition because he had strong views on what the flag should represent but he couldn’t draw one himself. More>>

ALSO:

Books: The Lawson Quins Tell Their Incredible Story

They could have been any family of six children – except that five of them were born at once. It will come as a shock to many older New Zealanders to realise that Saturday July 25 is the Lawson quintuplets’ 50th birthday. More>>

Scoop Review Of Books: Wartime Women

Coinciding as it does with the movie Imitation Game which focusses on Alan Turing breaking the Enigma code in Hut 6 at Bletchley Park (“BP”), this book is likely to attract a wide readership. It deserves to do so, as it illustrates that BP was very much more than Turing and his colleagues. More>>

Maori Language Commission: Te Wiki O Te Reo Māori 2015

The theme for Māori Language Week 27 July – 2 August 2015 is ‘Whāngaihia te Reo ki ngā Mātua’ ‘Nurture the language in parents’. It aims to encourage and support every day Māori language use for parents and caregivers with children” says Acting Chief Executive Tuehu Harris.. More>>

ALSO:

Live Music: Earl Sweatshirt Plays To Sold Out Bodega

The hyped sell-out crowd had already packed themselves as close as they could get to the stage before Earl came on. The smell of weed, sweat and beer filled Bodega – more debauched sauna than bar by this point. When he arrived on stage the screaming ... More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news